Monday, August 22, 2022 7:19:53 AM
I guess you want to strike while the iron is hot, but I expected them to wait a LITTLE longer to pick up some cash.
Hoping that the lessons from 05 help the 07 approval to move faster.
Hoping that the lessons from 05 help the 07 approval to move faster.
Recent AXSM News
- Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
- Axsome Therapeutics Recognizes Mental Health Month • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 09:55:09 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 05/05/2026 09:54:01 PM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 09:43:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 09:04:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 11:07:33 AM
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/04/2026 11:00:00 AM
- Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader • GlobeNewswire Inc. • 05/01/2026 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 09:19:05 PM
- Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease • GlobeNewswire Inc. • 04/30/2026 06:06:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 09:02:38 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 09:01:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:02:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:01:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:00:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:00:20 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:03:36 PM
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 11:05:09 AM
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions • GlobeNewswire Inc. • 04/01/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2026 12:10:07 AM
